When initiating either empagliflozin or dulaglutide, the newly funded second-line type 2 diabetes agents,choice is based primarily on predominant comorbidities, clinical features and tolerability.

Administration route is an additional factor; dulaglutide is a once-weekly, subcutaneous injection and empagliflozin is a daily tablet. Patient factors are also important, and the contraindications and adverse effects profiles differ. 

Read the HAH Bulletin to find out more.

Contributor
He Ako Hiringa
17 August 2021

Prescribers wanting to block angiotensin II effects can consider the remaining funded ACE inhibitors or angiotensin II receptor blockers. ACE inhibitors and ARBs are similarly effective for hypertension, chronic renal disease and diabetic nephropathy, but ARBs are better tolerated.2 ACE inhibitors are preferred over ARBs first-line for heart failure and post myocardial infarction.2

Read the HAH Bulletin to find out more.

Contributor
He Ako Hiringa
19 July 2021
2 minutes to Delve

Medicine affordability is one of the five drivers of medicine access equity.

Up to 40 per cent of people continue to pay prescription copayments even though they are entitled to an exemption.No person or family should pay more than $100 per annum for subsidised medicines.

Read the HAH bulletin to find out more. 

Contributor
He Ako Hiringa
30 April 2021